Established life sciences executive with leadership roles at multiple companies in the life sciences space
- Interim CEO, Brooklyn ImmunoTherapeutics (current)
- Previous CEO and Board roles at multiple biopharma companies, achieving product launches and M&A exits
- Led the development and launch of Biogen flagship product Avonex in US and internationally
Mark Leuchtenberger, MBA, is also currently Interim CEO of Brooklyn ImmunoTherapeutics and formerly Chairman, President and CEO of IRX Therapeutics. Mr. Leuchtenberger has over 20 years of experience as a senior executive in the biopharmaceutical industry where he has led companies through private financings and initial public offerings, taken products from IND through to commercialization and achieved M&A exits. Mr. Leuchtenberger was President and Chief Executive Officer and a member of the board of directors at Chiasma (NASDAQ: CHMA), Acusphere, Inc., Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics, Inc.) and served as President and CEO of Targanta Therapeutics Corporation, and Therion Biologics Corporation. Prior to Therion, Mr. Leuchtenberger was a senior officer at Biogen Inc., where he led the late-stage development of Avonex and its commercialization in the United States and internationally in 65 countries. He is a director and past chairman of the Massachusetts Biotechnology Council Board of Directors and is a cofounder of Albor Biologics, Inc. and Alvos Therapeutics, Inc. Mr. Leuchtenberger received his MBA from the Yale School of Management and his BA from Wake Forest University.